Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/27506| Title: | Diffuse large B-cell lymphoma: A consensus practice statement from the Australasian Lymphoma Alliance. | Austin Authors: | Wight, Joel C ;Hamad, N;Campbell, B A;Ku, M;Lee, K;Rose, H;Armytage, T;Latimer, M;Lee, H P;Lee, Sze Ting ;Dickinson, M;Khor, Richard ;Verner, E | Affiliation: | Department of Haematology, Concord Repatriation General Hospital, Sydney, New South Wales, Australia Austin Health James Cook University, Townsville, Australia School of Medicine, University of Sydney, Sydney, New South Wales, Australia Anatomical Pathology Department, NSW Health Pathology, Concord Repatriation General Hospital, Sydney, New South Wales, Australia Canberra Hospital, Canberra, Australia Australian National University, Canberra, Australia Flinders Medical Centre, Adelaide, Australia St Vincent's Hospital, Melbourne, Victoria Department of Haematology, Peter MacCallum Cancer Centre, Parkville, Victoria School of Medicine, Deakin University Geelong, Victoria Department of Clinical Pathology, University of Melbourne, Parkville, Victoria Department of haematology, Gosford Hospital, Gosford, New South, UK St Vincent's Clinical School, Sydney, University of New South UK Department of Haematology, St Vincent's Hospital Sydney, Australia School of Medicine, Sydney, University of Notre Dame Australia Department of Radiation oncology, Peter MacCallum Cancer Centre, Parkville, Victoria University Hospital Geelong, Victoria The University of Melbourne, Melbourne, Australia Townsville University Hospital, Townsville, Australia |
Issue Date: | 16-Sep-2021 | Date: | 2021-09-16 | Publication information: | Internal Medicine Journal 2021; online first: 16 September | Abstract: | Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype, accounting for 30-40% of lymphoma diagnoses. Though aggressive, cure is achievable in approximately 60% of cases with primary chemo-immunotherapy, and in a further substantial minority by salvage therapy and autologous stem cell transplantation. Despite promising activity in early phase clinical trials, no intensified or novel treatment regimen has improved outcomes over R-CHOP21 in randomised studies. However, there remain several areas of controversy including the most appropriate prognostic markers, CNS prophylaxis and the optimal treatment for patients with high-risk disease. This position statement presents an evidence-based synthesis of the literature for application in Australasian practice. This article is protected by copyright. All rights reserved. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/27506 | DOI: | 10.1111/imj.15533 | ORCID: | 0000-0002-3216-2392 0000-0001-7929-1450 0000-0002-9289-1335 0000-0001-8641-456X 0000-0002-1492-5966 |
Journal: | Internal Medicine Journal | PubMed URL: | 34532916 | Type: | Journal Article | Subjects: | DLBCL diagnosis management prognosis |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.